AstraZeneca gets Chinese approval for diabetes drug Xigduo XR
AstraZeneca has secured approval for Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) from China’s National Medical Products Administration (NMPA) for the treatment of adults with type-2 diabetes (T2D).